68Ga-NOTA-exendin-4 PET/CT for the Localization of Insulinoma and Diagnosis of Nesidioblastosis
Status:
Unknown status
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
This is an open-label positron emission tomography/computed tomography (PET/CT) study to
investigate the diagnostic performance and evaluation efficacy of 68Ga-NOTA-exendin-4 in
insulinoma and nesidioblastosis patients. A single dose of 55.5-111 Mega-Becquerel (MBq)
68Ga-NOTA-exendin-4 will be injected intravenously. Visual and semiquantitative method will
be used to assess the PET/CT images.
Phase:
Early Phase 1
Details
Lead Sponsor:
Peking Union Medical College Hospital
Collaborator:
National Institute for Biomedical Imaging and Bioengineering (NIBIB)